Lilly announces promising updates on olomorasib in KRAS G12C-mutant cancers at ASCO 2024

Eli Lilly and Company (Lilly, NYSE: LLY) has released updated data from its ongoing Phase 1/2 clinical trial for olomorasib, showcasing significant advancements in the ... Read More